Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

Alphabet's Isomorphic Labs pulls in $5 billion to speed AI drug push toward trials

Published Nov 17, 2026
Share:
Summary:
  • Isomorphic Labs raised $5 billion in a Series C led by Sequoia Capital and Greenoaks, with Andreessen Horowitz joining and prior backers including Thrive Capital, GV and CapitalG participating.
  • CEO Demis Hassabis says the cash will accelerate the path to clinical trials and build a platform aimed at producing hundreds of drug candidates each year.
  • The raise lands about six months after a $2.1 billion fundraise in May, with the company saying it will announce the round Tuesday.

Who wrote the check and why it matters

Isomorphic Labs, the London-based AI drug discovery unit founded in 2021 to extend Google DeepMind's AlphaFold breakthroughs, has secured $5 billion in fresh capital. Sequoia Capital and Greenoaks are co-leading the Series C that the company plans to unveil Tuesday, joined by new investor Andreessen Horowitz and returning investors Thrive Capital, GV and CapitalG. The company did not share a valuation, though Bloomberg previously said the round targeted $5 billion at about a $50 billion valuation.

The war chest follows a May raise of $2.1 billion. Isomorphic is running its own target discovery work in cancer, immune conditions and inflammation, while also partnering with Eli Lilly, Novartis and Johnson & Johnson.

What the money builds

The plan, according to CEO Demis Hassabis: push faster toward human testing and scale a platform designed to generate a very large pipeline. "What we're trying to build is a platform to do hundreds of drugs a year," he said, adding the focus is on technologies and infrastructure that enable that at scale rather than any single program. The company says it has more than 20 programs in motion and is approaching preclinical work on its first oncology effort.

Earlier this year, Hassabis said the first clinical trial might start before 2026 draws to a close. In a November interview, he declined to give a new timeline for the initial cancer target, but said regulatory filings are progressing and that there will be more news in 2027.

Another goal for this raise is breadth. Isomorphic has emphasized small molecule drugs to date, and Hassabis said the company now wants to pursue "pretty much all modalities," moving into macromolecules (biologics) and other medicine types to reach more targets.

Savvy investors often look to new tools to gain a subtle advantage. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.

The AI drug race and the edge backers see

No medicine designed by AI has yet been cleared by regulators. The field is getting more crowded, though, with newcomers like Chai Discovery and listed players such as Insilico Medicine, which is running a late-stage clinical trial in China of an AI-discovered therapy.

According to Konstantine Buhler, a partner at Sequoia, his firm's confidence stems from how Isomorphic builds its models. He pointed to identified scaling laws - patterns that guide how models improve with added compute and data - as the reason Sequoia believes the company can hit clinical testing. "That's huge, because you at least know where you're going. You're not just throwing capital and resources blindly - you're highly informed," Buhler said.

Alphabet ties, compute supply and the investor takeaway

This is Isomorphic's first fundraise since Alphabet's August shuffle, which shifted Hassabis from Google DeepMind CEO to chair of that division and Alphabet's chief scientist. After more than 15 years running DeepMind and nearly three years overseeing Google's combined AI work, he said the new roles let him focus on guiding the science. Waymo, Alphabet's self-driving unit, is another example of an in-house project that has tapped outside capital and debt to grow.

Compute access remains a swing factor for AI startups. Following Nvidia CEO Jensen Huang's resignation last week, some companies have fretted about chip supply. Hassabis said Isomorphic has "very secure compute pipelines," noting the "advantage" of being close to Google's cloud and other resources.

Google also designs its own chips that compete with Nvidia's offerings. "We've got a lot of ways we can deal with whatever comes," he said.

The bottom line: heavyweight investors are backing scale in AI-first drug discovery. Watch for whether Isomorphic converts its expanded modality reach, 20-plus programs and oncology preclinical milestone into regulatory filings on the 2026 to 2027 timetable - a set of catalysts that could reset how markets price AI-led biotech.

Learning how artificial intelligence can inform decisions can sharpen long term results. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.

Disclosure

Recent News

1 2 3 … 130

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
November 14, 2026
Rare Earth Stocks: Why China's January 2027 Ban Could Be the Opportunity of the Decade
  • China plans to block rare earth exports to the US on January 10, 2027, and the US produces effectively zero of the 17 metals that go into phones, cars, dishwashers, and missiles.
  • When China cut off Japan in 2010 and squeezed Germany from 2015, some rare earth prices jumped 18x and 15x, and one rare earth company went bankrupt while another soared.
  • Washington is already putting billions into MP Materials, Vulcan, and a stockpile called Project Vault, and Jaspreet Singh walks through how investors can get exposure to rare earth stocks and ETFs.
Read More
1 2 3 … 33
Share via
Copy link